Biotech Veteran and Virologist Joins CancerVax as Senior Scientific Advisor
MWN-AI** Summary
CancerVax, Inc., based in Lehi, Utah, recently announced the appointment of Dr. George Kemble as Senior Scientific Advisor. Renowned for his expertise in virology, vaccines, and biologics, Dr. Kemble brings a wealth of experience to CancerVax, a company pioneering a universal cancer treatment platform designed to harness the body’s immune system to combat cancer effectively.
Dr. Kemble's career includes notable roles in various biotech firms, including his recent position as Chairman of the Board at Sagimet Biosciences, a clinical-stage biopharmaceutical company focused on innovative treatments for cancer and other diseases. His leadership at Sagimet spanned several critical areas, including medicinal chemistry and product development, particularly the lead candidate denifanstat. Prior to his time at Sagimet, he served as senior vice president of R&D at MedImmune, an AstraZeneca subsidiary, where he played a key role in developing FluMist®, the first major innovation in influenza vaccination in over six decades.
At CancerVax, Dr. Kemble's insight is expected to be instrumental as the company progresses with its distinctive approach. The core concept behind CancerVax involves reprogramming the immune system to recognize and target cancer cells by disguising them to resemble foreign viruses, thus triggering a robust immune response. Dr. Kemble emphasized the potential of CancerVax's strategy, likening cancer treatment to vaccination processes that teach the immune system to identify threats effectively.
Dr. George Katibah, Chief Scientific Officer of CancerVax, highlighted Dr. Kemble's unique combination of scientific acumen and executive experience, which will be critical as the company seeks to refine its groundbreaking platform. This innovative technology promises a future where cancer treatment could be as simple and accessible as receiving routine vaccinations.
MWN-AI** Analysis
The recent appointment of Dr. George Kemble as Senior Scientific Advisor at CancerVax signals significant potential for the company and may represent an intriguing opportunity for investors in the biotech sector. Dr. Kemble’s extensive background in virology, vaccine development, and executive leadership places him in a prime position to enhance CancerVax's innovative approach to cancer treatment.
CancerVax is pioneering a universal cancer treatment platform, leveraging the immune system to treat various cancers by mimicking common viral infections. This mechanism aims to "trick" the immune system into attacking cancer cells as it would foreign pathogens. Given the growing emphasis on immunotherapy within oncology, CancerVax’s strategy could align well with market trends, particularly as more traditional treatment modalities face limitations.
Dr. Kemble's previous success at Sagimet Biosciences, where he played a pivotal role in developing therapies targeting cancer and other diseases, adds credibility and optimism regarding CancerVax's direction. His insights into successful product development could streamline operational efficiencies and accelerate clinical advancements for CancerVax’s offerings. Furthermore, his track record during his tenure at MedImmune, especially the launch of FluMist®, underscores his capability to bring innovative therapies to market.
Investors should note that CancerVax remains in the pre-clinical stage, suggesting inherent risks typical of early-stage biotech investments. However, the biotech landscape is characterized by volatility often accompanied by significant upside potential. Solid advancements in their R&D pipeline could lead to heightened investor interest and capital appreciation.
In summary, with Dr. Kemble on board, CancerVax appears poised for substantial growth potential in the biotech arena. Investors, however, should maintain a cautious approach and evaluate the forthcoming clinical milestones to gauge the company's trajectory in this highly competitive market.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Lehi, Utah, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Lehi, Utah, January 27, 2026 – CancerVax, Inc., the developer of a breakthrough universal cancer treatment platform that uses the body’s immune system to treat cancer, today announced that George Kemble, PhD will serve as a Senior Scientific Advisor.
Dr. Kemble is a veteran biotech executive and scientist with a specialty focus in the areas of virology, vaccines and small molecule biologics. Dr. Kemble is currently the Chairman of the Board at Sagimet Biosciences Inc. (NASDAQ: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors for cancer treatment, liver fibrosis, acne and other diseases. He joined Sagimet in August 2011 as its chief scientific officer and served as CEO from October 2015 until October 2022, when he transitioned to the role of executive chairman. In May 2025, Dr. Kemble moved into the role of non-executive Chair of the Board. At Sagimet, he directed medicinal chemistry, research, translational and CMC groups, and worked on several programs including the lead product candidate, denifanstat.
Prior to Sagimet, Dr. Kemble served as the senior vice president of R&D and head of research at MedImmune, Inc., a subsidiary of AstraZeneca PLC. During his tenure, he was responsible for a large group of scientists dedicated to the research and development of programs across a number of therapeutic areas, including the launch of FluMist®, the first innovation in influenza vaccines in over 60 years. Dr. Kemble received a BS degree from the University of Santa Clara, a PhD from Stanford University and completed post-doctoral training at UCSF, where he worked on various human viruses.
CancerVax was founded on the idea that disguising cancer cells to resemble foreign viruses can effectively “trick” the immune system into recognizing and aggressively attacking them.
Dr. Kemble commented, “The human body is quite amazing at fighting foreign viruses through adaptive immunity such as prior infection or vaccination. Cancer, on the other hand, is a disease that originated from healthy cells and the body has a hard time recognizing it as foreign. There’s a lot of work in the field that tries to teach the immune system what cancer looks like. CancerVax’s approach of making cancer look like well immunized diseases, such as chickenpox or measles, is a very interesting approach. I look forward to helping.”
“Dr. Kemble brings a rare combination of deep virology expertise, vaccine innovation, and executive leadership to CancerVax,” said Dr. George Katibah, Chief Scientific Officer of CancerVax. “His career has been defined by translating fundamental immunology into real-world therapies, and his perspective will be invaluable as we advance our platform that reframes cancer as a target that the immune system already knows how to defeat.”
To learn more about the CancerVax platform, please watch the Short Explainer Video at https://cancervax.com/explainer
About CancerVax
CancerVax is a pre-clinical biotech company developing a novel Universal Cancer Treatment platform that will be customizable, as an injection, to treat many types of cancer. Our innovative approach DETECTS, MARKS, and KILLS only cancer cells. By making cancer cells look like well-immunized common diseases, such as measles or chickenpox, we intend to use the body's natural immune system to easily kill the cancer cells. We look forward to the day when treating cancer will be as simple as getting a shot — a better way to fight cancer. To learn more, please visit www.CancerVax.com
Forward-Looking Statements
This press release may contain "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations, and assumptions regarding the future of our business, plans and strategies, projections, anticipated events and trends, the economy, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict, many of which are outside our control. Our actual results and financial condition may differ materially from those in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Any forward-looking statement made by us in this release is based only on information currently available to us and speaks only as of the date it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments, or otherwise.
Press Contact:
CancerVax, Inc.
Tel: (805) 356-1810
communications@CancerVax.com
FAQ**
How might George Kemble's experience with Sagimet Biosciences Inc. (SGMT) influence his role at CancerVax, particularly in terms of guiding the development of innovative cancer treatments?
What synergies could exist between CancerVax's platform and the therapeutic areas in which Sagimet Biosciences Inc. (SGMT) specializes, such as cancer treatment and liver fibrosis?
Given Dr. Kemble's prior leadership at Sagimet Biosciences Inc. (SGMT), what strategic insights could he bring to CancerVax as it aims to advance its universal cancer treatment platform?
How does CancerVax intend to leverage the principles of immunology, similar to those explored in Sagimet Biosciences Inc. (SGMT)'s research, to enhance the efficacy of its cancer treatment approach?
**MWN-AI FAQ is based on asking OpenAI questions about Sagimet Biosciences Inc. (NASDAQ: SGMT).
NASDAQ: SGMT
SGMT Trading
-1.84% G/L:
$5.345 Last:
155,712 Volume:
$5.21 Open:
